Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00422019 | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 61 | AmgenINDUSTRY | 0 | Apr 10, 2015 | clinicaltrials |
| NCT00050323 | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01720693 |
| Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy |
| terminated |
| Phase 2 |
| 3 |
| University Health Network, TorontoOTHER |
| 1 |
| Feb 11, 2015 |
| clinicaltrials |
| NCT01791387 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC(DILIGENCE-1) | unknown | Phase 2 | 30 | Auckland District Health BoardOTHER_GOV | 1 | Feb 3, 2015 | clinicaltrials |
| NCT00126503 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00661375 | BAY43-9006 Phase II Study for Renal Cell Carcinoma | completed | Phase 2 | 131 | BayerINDUSTRY | 1 | Dec 25, 2014 | clinicaltrials |
| NCT02324803 | Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | unknown | Phase 2 | 86 | Southern China Urology Cancer ConsortiumOTHER | 1 | Dec 24, 2014 | clinicaltrials |
| NCT01034878 | Sunitinib in Metastatic Renal Cancer | completed | Phase 2 | 25 | Istituto Clinico HumanitasOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00044564 | Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 54 | BayerINDUSTRY | 6 | Dec 19, 2014 | clinicaltrials |
| NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | completed | Phase 2 | 501 | BayerINDUSTRY | 2 | Dec 19, 2014 | clinicaltrials |
| NCT01274273 | Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer | unknown | Phase 2 | 118 | University of AarhusOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01967407 | IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.(IRENE) | unknown | Phase 1 / Phase 2 | 20 | University of MagdeburgOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00117637 | BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 189 | BayerINDUSTRY | 7 | Oct 31, 2014 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00520403 | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | completed | Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00570882 | Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 76 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT01408004 | Rotating Pazopanib and Everolimus to Avoid Resistance(ROPETAR) | completed | Phase 2 | 101 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00265135 | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 68 | Centocor, Inc.INDUSTRY | 4 | Jul 3, 2014 | clinicaltrials |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | terminated | Phase 2 | 49 | Queen Mary University of LondonOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT00515697 | A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00918281 | Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection | completed | Phase 2 | 70 | GE HealthcareINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00471536 | Pazopanib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | May 30, 2014 | clinicaltrials |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00081614 | A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Apr 29, 2014 | clinicaltrials |
| NCT00353301 | Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | completed | Phase 2 | 25 | University of Colorado, DenverOTHER | 1 | Apr 14, 2014 | clinicaltrials |
| NCT01577784 | Pazopanib in Second-line Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 27 | Associació per a la Recerca Oncologica, SpainOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00891475 | Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 / Phase 2 | 114 | Kidney Cancer Research BureauOTHER | 1 | Feb 13, 2014 | clinicaltrials |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 30 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00586495 | Long-term Extension From RCC Phase II (11515) | completed | Phase 2 | 95 | BayerINDUSTRY | 1 | Dec 13, 2013 | clinicaltrials |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 1 | BayerINDUSTRY | 1 | Oct 11, 2013 | clinicaltrials |
| NCT01939756 | Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms(Baobab) | completed | Phase 1 / Phase 2 | 50 | Savino M. Di StasiOTHER | 1 | Sep 11, 2013 | clinicaltrials |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 40 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00059813 | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | Accelerated Community Oncology Research NetworkOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00678119 | Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment | completed | Phase 2 | 25 | Argos TherapeuticsINDUSTRY | 2 | Jul 15, 2013 | clinicaltrials |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00354250 | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 10, 2015source: clinicaltrials